Clinical trial · Interventional
18F-grazy-02 PET/CT of Granzyme B Expression for Monitoring Immunotherapy
18F-grazy-02 PET/CT of Granzyme B Expression for Monitoring Immunotherapy in Patients With Lymphoma or Solid Tumors
NCT07724535CI-TRIAL-00120026recruitingPhase 1 / Phase 2ClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
This is an open-label PET/CT study to investigate the safety and clinical monitoring value of 18F-grazy-02 in patients with lymphoma or solid tumors receiving immunotherapy, including immune checkpoint inhibition and CAR-T cell therapy.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Cancer | Malignant Neoplasm | ALIAS | 0.90 |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| 18F-grazy-02 | Drug | — | UNRESOLVED |
Design
Arms and outcomes
Arms (1)
- type
- EXPERIMENTAL
- label
- experimental 18F-grazy-02 PET/CT imaging
- description
- The purpose of the study is to evaluate the safety and early monitoring performance of 18F-grazy-02 for immunotherapy.
- interventionNames
- Drug: 18F-grazy-02
Primary outcomes (2)
- measure
- Incidence of 18F-grazy-02-emergent Adverse Events
- timeFrame
- 1 year
- description
- Any adverse events following the administration of the radiotracer will be monitored.
- measure
- Biodistribution of 18F-grazy-02 in participants
- timeFrame
- 1 year
- description
- The distribution of 18F-grazy-02 in tumors and healthy tissues will be examined through PET/CT imaging.
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
- Maximum age
- 75 Years
Show eligibility criteria text
Inclusion Criteria: 1. 18-75 years old; 2. ECOG score 0 or 1 point; 3. Participants with suspected or confirmed non-small cell lung cancer or melanoma who are suggested by the clinicians to conduct PET/CT imaging for tumor diagnosis or staging. Exclusion Criteria: 1. Pregnant or nursing; 2. Severe hepatic or renal dysfunction; 3. Low WBC (less than 3 x 10\^9/L); 4. Unable to comply with the PET/CT imaging procedures.
References
Publications (0)
Data not yet available
No reference posted for this study.